Study Of Diabetic Nephropathy With Atrasentan (SONAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01858532|
Recruitment Status : Terminated (Strategic considerations)
First Posted : May 21, 2013
Last Update Posted : April 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Drug: Atrasentan Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5112 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan|
|Actual Study Start Date :||May 17, 2013|
|Actual Primary Completion Date :||March 29, 2018|
|Actual Study Completion Date :||March 29, 2018|
Active Comparator: Atrasentan
Subjects randomized to the atrasentan arm will receive active drug, atrasentan.
Oral daily low dose for 48 months.
Placebo Comparator: Placebo
Subjects randomized to the placebo arm will receive placebo.
Oral daily dosing for 48 months.
- Time to the first occurrence of a component of the composite renal endpoint. [ Time Frame: Approximately 48 months. ]Time to the first occurrence of a component of the composite renal endpoint: doubling of serum creatinine (confirmed by a 30-day serum creatinine) or the onset of end stage renal disease (estimated glomerular filtration rate (eGFR) less than 15 ml/min/1.73 m2 confirmed by a 90-day eGFR, receiving chronic dialysis, renal transplantation or renal death).
- Time to first occurrence of a component of composite renal endpoint: confirmed doubling of serum creatinine or the onset of end stage renal disease for all randomized subjects (pooled). [ Time Frame: Approximately 48 months. ]
- Time to a 50% estimated glomerular filtration rate reduction. [ Time Frame: Approximately 48 months. ]
- Time to the cardiovascular composite endpoint: cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. [ Time Frame: Approximately 48 months. ]
- Time to cardio-renal composite endpoint: confirmed doubling of serum creatinine, end stage renal disease, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke. [ Time Frame: Approximately 48 months. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01858532
Show 796 Study Locations
|Study Director:||AbbVie Inc.||AbbVie|